Tim’s early research in the industry focused on Immunomodulation and Imaging to study of effects on T-cell lymphocyte homing. He held several managerial positions in Image Informatics and came to the organization in 2006 to begin work as Director of Image Informatcs. His role has expanded over the years to include Life Science Research Marketing and Product Management for Assay Management, Next Generation Sequencing, Sequence Analysis, Biotherapeutics, and Bio Registration.

1. What are you looking forward to discussing with the audience?

So many pharmaceutical and biopharmaceutical organizations are increasing their focus on biotherapeutic drug development in order to remain competitive in the market. Unfortunately, this can backfire when these organizations don’t take in to account the resources required for managing the additional complex data and processes involved. This can increase exposure to compliance risk, decrease overall productivity and extend the time to market for new products. I’m excited to have the opportunity to show the audience that there is a better way to not only manage, but leverage biologics data by eliminating inefficient paper-based workflows, reducing the effort for creating experiments, providing better understanding of processes and products, and much more.

2. You’ve mentioned that the biologics discovery workflow is similar to small molecule discovery at the highest level but that there are differences in the details. Can you explain what changes as an organization shifts toward biotherapeutic development?

In short, biologic discovery demands unique processes due to the added complexity of biological systems. Compared to small molecule discovery, biologics workflows generate a large amount and a large variety of complex data. However, being able to distill the information and track the genealogy of how to get to an end entity is critical. This requires some advanced data and workflow management.

3.  Why do you feel this topic is important?

In a recent market survey conducted by industry analysts IDC, it was shown that just 6 of the top-selling drugs in 2014 were biologics. In 2018 however, it’s estimated that over 50% of the top 100 prescription and OTC drug sales will be biologics. This clearly shows the strong industry trend shifting to biologics and with that industry shift, life science organizations will need a robust informatics solution to manage the increased complexity of biologics.

4. What do you hope the audience will learn from this webinar?

By attending this webinar, I hope the audience will see the true potential impact of transitioning from disjointed workflows and what has primarily been   a paper-based to an electronic Biologics solution covering all activities of the discovery process and how that positively affects their bottom line.

Join Tim in the BIOVIA webinar ‘Integrated, Predictive and Collaborative Workflows in Biologics Discovery‘. Register now!